Table 1. IHC analysis of AnxA6 expression in normal tissues and cancer tissues using MAb 9E1.
| Normal tissue | AnxA6 expression as revealed by MAb 9E1 staining |
|---|---|
| Colon | Weak positivity (non-proliferating cells) |
| Pancreas | Weak-moderate positivity associated with islets |
| Gastric epithelium | Weak/moderate positivity, isolated areas (1+/2+) |
| Breast | Weak positivity isolated areas (1+) (<10% of tissue) |
| Lung | Negative |
| Oesophagus | Non-specific staining |
| Duodenum | Weak positivity |
| Liver | Negative |
| Tonsil | Staining in areas surrounding germinal centres (non-proliferating cells, no staining in Ki-67-positive cells) |
| Kidney | Weak/moderate (1+/2+) positivity in some tubules |
| Cervix | Negative |
| Cancer | AnxA6 expression as revealed by MAb 9E1 staining |
| PDAC | 57/57 (100%) |
| Colon adenocarcinoma KRAS wt | 5/5 (100%) |
| Colon adenocarcinoma KRAS mt | 5/5 (100%) |
| Breast, HER-2 positive | 56/70 (80%) |
| Breast, TNBC | 6/6 (100%) |
| Lung adenocarcinoma | 7/9 (77.8%) |
| Lung large cell | 6/8 (75%) |
| Lung squamous | 22/27 (81.5%) |
| Lung small cell differentiated | 3/5 (60%) |
| Lung complexed small cell and squamous cell carcinoma | 4/5 (80%) |
| Melanoma | 2/2 (100%) |
| Renal carcinoma | 2/2 (100%) |
Abbreviations: AnxA6=annexin a6; MAb=monoclonal antibody; PDAC=pancreatic adenocarcinoma.